Zanaflex: Targeted Muscle Spasm Relief with Tizanidine
Zanaflex
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | 4.68 $ | 46.80 $ (0%) | 🛒 Add to cart |
| 20 | 2.92 $ | 93.60 $ 58.50 $ (37%) | 🛒 Add to cart |
| 30 | 2.34 $ | 140.40 $ 70.20 $ (50%) | 🛒 Add to cart |
| 60 | 1.56 $ | 280.80 $ 93.60 $ (67%) | 🛒 Add to cart |
| 90 | 1.43 $ | 421.20 $ 128.70 $ (69%) | 🛒 Add to cart |
| 120 | 1.36 $ | 561.60 $ 163.80 $ (71%) | 🛒 Add to cart |
| 180 | 1.04 $ | 842.40 $ 187.20 $ (78%) | 🛒 Add to cart |
| 270 | 0.95 $ | 1263.60 $ 257.40 $ (80%) | 🛒 Add to cart |
| 360 | 0.93 $
Best per pill | 1684.80 $ 333.45 $ (80%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Zanaflex (tizanidine hydrochloride) is a short-acting muscle relaxant indicated for the management of acute muscle spasticity. It functions as a central alpha-2-adrenergic agonist, effectively reducing the frequency and amplitude of muscle spasms without directly impairing neuromuscular function. This medication is commonly prescribed for conditions such as multiple sclerosis, spinal cord injury, and other neurological disorders causing spasticity. Proper dosing and medical supervision are essential to maximize therapeutic outcomes and minimize potential adverse effects.
Features
- Active ingredient: Tizanidine hydrochloride
- Available in 2 mg and 4 mg tablet strengths
- Short half-life of approximately 2.5 hours
- Central alpha-2-adrenergic agonist mechanism
- FDA-approved for acute muscle spasticity management
- Requires individualized dosing based on patient response and tolerability
Benefits
- Reduces the frequency and intensity of painful muscle spasms
- Improves range of motion and functional mobility in spasticity-related conditions
- May enhance comfort during physical therapy and daily activities
- Short-acting nature allows for flexible dosing around specific needs (e.g., nighttime spasm relief)
- Can be used as an adjunct therapy in comprehensive spasticity management plans
- Helps decrease muscle tone hyperreflexia in eligible patients
Common use
Zanaflex is primarily prescribed for the management of acute muscle spasticity resulting from neurological conditions. It is frequently used in patients with multiple sclerosis, spinal cord injuries, and certain stroke-related spasticity presentations. The medication helps alleviate muscle tightness, involuntary contractions, and associated discomfort, thereby supporting rehabilitation efforts and improving quality of life. It is typically employed when non-pharmacological interventions prove insufficient.
Dosage and direction
The initial dose is usually 2 mg, taken orally up to three times daily, with a minimum 6- to 8-hour interval between doses. Dosage may be gradually increased in 2–4 mg increments, based on individual patient response and tolerability, with a maximum recommended daily dose of 36 mg. Doses should be taken with or without food consistently to avoid variability in absorption. Due to the risk of hypotension, patients should be advised to avoid sudden changes in posture. Always follow the specific dosing instructions provided by the healthcare provider.
Precautions
Zanaflex may cause sedation, dizziness, or hypotension, particularly upon initiation or dose adjustment. Patients should avoid activities requiring mental alertness, such as driving or operating machinery, until they know how the medication affects them. Caution is advised in elderly patients and those with renal or hepatic impairment, as clearance may be reduced. Alcohol and other CNS depressants should be avoided due to additive sedative effects. Regular monitoring of liver function may be recommended during prolonged therapy.
Contraindications
Zanaflex is contraindicated in patients with known hypersensitivity to tizanidine or any component of the formulation. Concurrent use with potent CYP1A2 inhibitors, such as fluvoxamine or ciprofloxacin, is contraindicated due to significantly increased tizanidine plasma levels and risk of adverse effects. It should not be used in patients with severe hepatic impairment.
Possible side effect
Common side effects include dry mouth, somnolence, asthenia, dizziness, and hypotension. Less frequently, patients may experience bradycardia, hallucinations, elevated liver enzymes, or visual disturbances. In clinical trials, some individuals reported nausea, nervousness, and urinary frequency. Most side effects are dose-dependent and may diminish with continued use or dose adjustment. Patients should report any persistent or severe symptoms to their healthcare provider.
Drug interaction
Zanaflex interacts significantly with CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), which can markedly elevate tizanidine levels. Concurrent use with other alpha-2-adrenergic agonists may enhance hypotensive and sedative effects. Alcohol, benzodiazepines, opioids, and other CNS depressants can potentiate sedation and dizziness. Oral contraceptives may reduce tizanidine clearance. Caution is advised when using with antihypertensives due to additive blood pressure-lowering effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to compensate for a missed one is not recommended, as it may increase the risk of adverse effects.
Overdose
Symptoms of overdose may include severe drowsiness, hypotension, bradycardia, respiratory depression, and coma. Management involves supportive care, including monitoring of vital signs and airway protection. Activated charcoal may be considered if ingestion was recent. There is no specific antidote for tizanidine overdose. In cases of significant hypotension, intravenous fluids and vasopressors may be administered under medical supervision.
Storage
Store Zanaflex tablets at room temperature (20–25°C or 68–77°F), in a tightly closed container, and protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused medication according to local guidelines or through a drug take-back program.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication. Individual patient needs and responses may vary.
Reviews
Clinical studies and patient reports generally indicate that Zanaflex is effective in reducing muscle spasticity and associated discomfort. Many users note improved mobility and sleep quality, though some report sedation or dizziness, especially at higher doses. Adherence to prescribed dosing and open communication with healthcare providers are frequently emphasized for optimal outcomes. Long-term user experiences often highlight the importance of regular follow-up to adjust dosage as needed.